Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the transaction, the director now directly owns 1,425 shares in the company, valued at approximately $41,524.50. This trade represents a 84.66 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Castle Biosciences Stock Performance

NASDAQ CSTL opened at $32.72 on Thursday. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm has a 50-day moving average price of $29.91 and a two-hundred day moving average price of $27.78. The company has a market capitalization of $916.39 million, a P/E ratio of 163.61 and a beta of 0.92. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The business had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. During the same quarter in the prior year, the business posted ($0.26) earnings per share. Analysts anticipate that Castle Biosciences, Inc. will post 0.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CSTL. Principal Financial Group Inc. increased its holdings in Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after buying an additional 40,377 shares during the period. Bellevue Group AG raised its position in Castle Biosciences by 3.7% during the third quarter. Bellevue Group AG now owns 1,262,030 shares of the company’s stock valued at $35,993,000 after purchasing an additional 44,929 shares in the last quarter. Portolan Capital Management LLC lifted its stake in Castle Biosciences by 3.7% during the third quarter. Portolan Capital Management LLC now owns 1,255,628 shares of the company’s stock worth $35,811,000 after purchasing an additional 44,676 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Castle Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock valued at $17,631,000 after purchasing an additional 60,675 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Castle Biosciences by 9.8% in the 3rd quarter. State Street Corp now owns 680,001 shares of the company’s stock valued at $19,394,000 after purchasing an additional 60,924 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. BTIG Research boosted their target price on Castle Biosciences from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Lake Street Capital increased their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Scotiabank lifted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 6th. Canaccord Genuity Group increased their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, October 29th. Finally, KeyCorp boosted their price objective on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences presently has an average rating of “Buy” and a consensus target price of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.